Chronic Liver Diseases Therapeutics Market Report 2026

The chronic liver diseases therapeutics market size has grown rapidly in recent years. It will grow from $15.88 billion in 2025 to $17.56 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to improved diagnosis of chronic liver conditions, expansion of antiviral therapy usage, increased management of autoimmune liver diseases, wider access to hospital-based liver care, growth of specialty hepatology services.

The chronic liver diseases therapeutics market size is expected to see rapid growth in the next few years. It will grow to $25.99 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing investments in NASH and fibrosis therapies, rising demand for precision liver medicine, expansion of biologic and targeted treatments, growing focus on early intervention strategies, increased clinical trial activity in liver diseases. Major trends in the forecast period include increasing development of targeted liver therapies, rising focus on disease-specific treatment approaches, growing adoption of combination drug regimens, expansion of non-invasive disease monitoring, enhanced emphasis on slowing disease progression.

Rising alcohol consumption is expected to support the growth of the chronic liver disease therapeutics market in the coming years. Alcohol consumption refers to the intake of beverages containing ethanol, ranging from moderate to excessive levels, and is associated with various health risks. The increase in alcohol consumption is driven by factors such as greater social acceptance, rising disposable incomes, and improved global accessibility. Chronic liver disease therapeutics help manage liver damage caused by excessive alcohol intake by slowing disease progression and supporting improved liver function. For example, in June 2024, First Citizens Bank, a US-based financial institution, reported a 1.2% increase in direct-to-consumer wine case sales in 2023 compared to 2022. Additionally, in December 2023, a report by Kirin Holdings Company Limited, a Japan-based beverage company, noted that approximately 192.1 million kiloliters of beer were consumed in 2022, representing a 2.9% increase from the previous year. Therefore, increasing alcohol consumption is contributing to the growth of the chronic liver disease therapeutics market.

Major companies operating in the chronic liver disease therapeutics market are concentrating on the development of innovative approaches such as engineered autologous macrophage cell therapy to improve liver regeneration, limit fibrosis progression, and deliver more targeted, disease-modifying treatment options. Engineered autologous macrophage cell therapy involves using a patient’s own macrophages that are modified or functionally enhanced outside the body and then reinfused to reduce liver inflammation, promote tissue repair, and slow or potentially reverse fibrosis in chronic liver diseases. For instance, in June 2024, Resolution Therapeutics Ltd., a UK-based biotechnology company, received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate its Phase I/II EMERALD study for its lead candidate, RTX001, aimed at treating decompensated liver cirrhosis.

In March 2024, Gilead Sciences Inc., a US-based pharmaceutical company, acquired CymaBay Therapeutics Inc. for approximately $4.3 billion. Through this acquisition, Gilead Sciences seeks to strengthen and expand its portfolio in liver disease treatments, with a particular focus on non-alcoholic steatohepatitis (NASH) and other chronic liver disorders. CymaBay Therapeutics Inc. is a US-based company dedicated to developing therapies for liver diseases, including chronic liver conditions.

Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy's Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

North America was the largest region in the chronic liver diseases therapeutics market in 2025. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chronic liver diseases therapeutics market by increasing costs of imported biologics, specialty drugs, active pharmaceutical ingredients, and advanced manufacturing inputs. North America and Europe are most affected due to reliance on global biologic supply chains, while Asia-Pacific faces pricing pressure on therapeutic exports. These tariffs are contributing to higher treatment costs and delayed market entry of new therapies. At the same time, they are encouraging regional drug manufacturing, local biologics production, and strategic investments in domestic liver disease therapeutics development.

The chronic liver diseases therapeutics market research report is one of a series of new reports that provides chronic liver diseases therapeutics market statistics, including chronic liver diseases therapeutics industry global market size, regional shares, competitors with a chronic liver diseases therapeutics market share, detailed chronic liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the chronic liver diseases therapeutics industry. This chronic liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic liver disease therapeutics encompass medical treatments and interventions intended to manage long-term liver conditions. These therapies aim to slow disease progression, relieve symptoms, and improve liver function through the use of medications, lifestyle modifications, and, in certain cases, advanced medical procedures.

The primary treatment categories for chronic liver disease therapeutics include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapies, and chemotherapy. Antiviral drugs are medicines developed to inhibit viral replication within the body, supporting the treatment and management of viral infections. These therapies are used across a range of disease types, such as hepatitis, autoimmune disorders, non-alcoholic fatty liver disease, cancer, and genetic conditions. Distribution occurs through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic liver disease therapeutics market includes revenues earned by entities by providing services such as genetic and molecular testing, liver transplantation, enzyme inhibitors, regular monitoring, and palliative and symptomatic care and related products, including pharmacological treatments, drugs, and emerging therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.